Journal of Cellular and Molecular Medicine · 2021 · 11 citations · 35 references
MedicineHematologyOncologyHematologic OncologyMolecular OncologyStem Cell BiologyCancer Stem Cell BiologyCancer Stem CellsHematologic MalignanciesHematopoietic Stem Cell BiologyHematopoietic Stem CellsMultiple MyelomaAcute Myeloid Leukemia TherapyAcute Myeloid Leukemia TreatmentChromosomal RearrangementsCyclin-dependent Kinase InhibitorsHematopoietic Stem Cell Leukemic TransformationMultiple Myeloma ChemotherapyMultiple Myeloma TherapyUnbalanced Chromosomal Rearrangements
Abstract Acute myeloid leukaemia (AML) with chromosomal rearrangements involving the H3K4 methyltransferase mixed‐lineage leukaemia (MLL) is an aggressive subtype with low overall survival. Bortezomib (Bort) is first applied in multiple myeloma. However, whether bort possesses anti‐self‐renewal and leukemogenesis of leukaemia stem cell (LSC) in AML with MLL rearrangements is still unclear. Here, we found that bort suppressed cell proliferation and decreased colony formation in human and murine leukaemic blasts. Besides, bort reduced the frequency and function of LSC, inhibited the progression, and extended the overall survival in MLL‐AF9 (MF9) ‐transformed leukaemic mice. Furthermore, bort decreased the percentage of human LSC (CD34 + CD38 ‐ ) cells and extended the overall survival in AML blasts‐xenografted NOD/SCID‐IL2Rγ (NSG) mice. Mechanistically, cyclin dependent kinase 6 ( CDK6 ) was identified as a bort target by RNA sequencing. Bort reduced the expressions of CDK6 by inhibiting NF ĸB recruitment to the promoter of CDK6 , leading to the abolishment of NF ĸB DNA‐binding activity for CDK6 promoter. Overexpression of CDK6 partially rescued bort‐induced anti‐leukemogenesis. Most importantly, bort had little side‐effect against the normal haematological stem and progenitor cell (HSPC) and did not affect CDK6 expression in normal HSPC. In conclusion, our results suggest that bort selectively targets LSC in MLL rearrangements. Bort might be a prospective drug for AML patients bearing MLL rearrangements.
35
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Tsvee Lapidot, Christian Sirard, Josef Vormoor et al. · Nature · 1994 · 4.7K citations
Medicine, Cell Biology, Hematology +14
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Andrei V. Krivtsov, David Twomey, Zhaohui Feng et al. · Nature · 2006 · 1.5K citations
The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival
Haizhen Wang, Brandon Nicolay, Joel M. Chick et al. · Nature · 2017 · 354 citations · Full text